Fate Therapeutics to Present at Guggenheim Healthcare Talks Idea Forum Oncology Day

On February 7, 2019 Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, reported that Dan Shoemaker, Ph.D., Chief Scientific Officer, will present at the Guggenheim Healthcare Talks Idea Forum Oncology Day in New York City on Thursday, February 14, 2019 at 3:30 p.m. ET (Press release, Fate Therapeutics, FEB 7, 2019, View Source [SID1234533182]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available through the investor relations section of the Company’s website at www.fatetherapeutics.com. Following the live webcast, an archived replay will be available on the Company’s website.

American Skin Association Announces 18 Promising, New Grants for Skin Cancer and Disease Research in 2019

On February 7, 2019 For more than three decades, American Skin Association (ASA) and its affiliates reported that have funded more than $50 million in grants to address the causes and treatments of melanoma, vitiligo, and psoriasis, as well as other skin diseases, and to search for much-needed cures (Press release, American Skin Association, FEB 7, 2019, View Source [SID1234554047]). Today, ASA continues its tradition of awarding significant research grants by funding 18 promising new grants for 2019.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This year, the much sought-after ASA Milstein Research Scholar Award for Melanoma/Non-melanoma Skin Cancer has been awarded to Neda Nikbakht, MD, PhD, Assistant Professor of Dermatology and Cutaneous Biology at Thomas Jefferson University in Philadelphia for her research on Genomic Profiling of Early Stage Cutaneous T-cell Lymphoma.

ASA renewed its commitment to Roger Lo, MD, PhD of the David Geffen School of Medicine at UCLA. Dr. Lo is midway through his work on a three-year award of the Abby S. and Howard P. Milstein Innovation Award for Melanoma/Non-Melanoma Skin Cancer Research (MIA). The grant of $750,000 was initially funded in 2018 and focuses on the field of cancer genetics and genomics, using next generation sequencing approaches to uncover the basis of resistance to both molecularly targeted therapies and immune checkpoint inhibitors.

These grants were made possible through the generosity of the Milstein Family. Howard P. Milstein, Chairman of ASA, and his family are devoted to funding vital dermatological research in an effort to discover cures for skin cancers and diseases.

"We are proud to continue our funding of crucial research through ASA. Although the skin is our largest and perhaps most vulnerable organ, dermatological research remains one of the most underfunded areas of medicine," said Mr. Milstein. "Through these grants we improve the chances of finding cures and bring hope to those suffering from devastating skin diseases."

Dr. Roger Lo, the MIA awardee, said, "I am very grateful for the continued generosity of Howard Milstein and his family. My lab is conducting patient-oriented melanoma research, the knowledge from which we will be able to use to directly impact patient management and care. This would not be possible without the support of individuals like Mr. Milstein."

ASA’s Medical Advisory Committee (MAC) is comprised of leading physicians and scientists who oversee the annual grant review and award process. Through MAC’s leadership, ASA’s grant program has supported the work of nearly 300 investigators, ranging from talented young researchers in the early phases of their careers to recognized leaders in the field of dermatology.

ASA President and Co-Chair of its MAC, Dr. David A. Norris, added, "We have a wonderful group of grant awardees this year. ASA’s Medical Advisory Committee is excited for the future findings of these important studies."

ASA provides significant special research awards to established investigators and medical students studying melanoma, non-melanoma skin cancer and skin diseases. Through these grants, ASA has promoted the early careers of many gifted young investigators and has had a profound impact both on dermatology research and clinical care of dermatologic disease. In particular, ASA-funded researchers have had a broad impact on melanoma research, improving our understanding of its diagnosis, treatment, and prognosis. With an exclusive focus on skin disease research, ASA has helped open new frontiers in skin science, producing results that can change how we understand and treat skin disease.

LIGAND ANNOUNCES OMNIAB® PARTNERSHIP WITH GENAGON THERAPEUTICS

On February 7, 2019 Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) reported it has entered into a worldwide OmniAb partnership with Genagon Therapeutics AB, an immuno-oncology focused biotech located in Sweden (Press release, Ligand, FEB 7, 2019, View Source [SID1234533127]). Under the terms of the partnership, Genagon gains access to the full OmniAb platform including OmniRat, OmniMouse, OmniFlic and OmniChicken in their drug discovery efforts. Ligand received an upfront payment and is eligible to receive development milestone payments and tiered royalties for each product incorporating an OmniAb-derived antibody. Genagon will be responsible for costs related to their programs.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"This agreement gives Genagon access to an industry-leading antibody discovery technology and the only platform to offer access to three species that produce fully-human antibodies. Genagon is focused on the immuno-oncology space, a promising area of current scientific research, and we are glad to welcome them as a partner", said John Higgins, Chief Executive Officer of Ligand. "The OmniAb platform is innovative and it has proven itself to be a broadly-licensable technology that we will continue to leverage as we build our Shots-on-Goal business model."

"We are very happy to partner with Ligand in gaining access to the OmniAb platform for developing ground-breaking antibody based therapeutics for immuno-oncology targeting novel suppressive pathways on antigen presenting cells discovered at Genagon," states Simon Fredriksson, Chief Executive Officer of Genagon.

Halozyme To Host Fourth Quarter And Full-Year 2018 Financial Results Webcast And Conference Call

On February 7, 2019 Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, reported that it will webcast its Quarterly Update Conference Call for the fourth quarter 2018 on Thursday, February 21 at 4:30 p.m. ET / 1:30 p.m. PT. Dr. Helen Torley, president and chief executive officer, will lead the call (Press release, Halozyme, FEB 7, 2019, View Source [SID1234533144]). On the same date, Halozyme will release financial results for the fourth quarter and year ended December 31, 2018 following the close of trading.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The call will be webcast live through the "Investors" section of Halozyme’s corporate website and a recording will be made available following the close of the call. To access the webcast and additional documents related to the call, please visit the Investors page of www.halozyme.com approximately fifteen minutes prior to the call to register, download and install any necessary audio software. The live call may be accessed by dialing (877) 410-5657 (domestic callers) or (334) 323-7224 (international callers) using passcode 387156. A telephone replay will be available after the call by dialing (877) 919-4059 (domestic callers) or (334) 323-0140 (international callers) using replay ID number 68892505

Arvinas Announces Poster Presentation at ASCO 2019 Genitourinary Cancers Symposium

On February 7, 2019 Arvinas Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on protein degradation, reported that it will present a poster at the 2019 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Genitourinary Cancers Symposium (ASCO GU), taking place February 14-16 in San Francisco (Press release, Arvinas, FEB 7, 2019, View Source [SID1234533163]). The presentation will highlight the company’s lead product candidate, ARV-110, an oral androgen receptor (AR)-targeted PROTAC (Proteolysis-Targeting Chimera) protein degrader for the treatment of men with metastatic castration-resistant prostate cancer. ARV-110 employs Arvinas’ proprietary PROTAC protein degradation technology.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation details are as follows:

Title: ARV-110: An oral androgen receptor PROTAC degrader for prostate cancer.
Abstract Number: 259
Poster: L16
Session Information: Poster Session A: Prostate Cancer
Session Date/Time: February 14; 11:30 a.m. – 1:00 p.m.; 5:30 – 6:30 p.m.
All abstracts for the Symposium will be released by ASCO (Free ASCO Whitepaper) on February 11, 2019 at 5:00 p.m. EST on meetinglibrary.asco.org.

About ARV-110
ARV-110 is an orally-bioavailable PROTAC protein degrader designed to selectively target and degrade androgen receptor (AR). ARV-110 is being developed as a potential treatment for men with metastatic castration-resistant prostate cancer (mCRPC). ARV-110 has demonstrated promising activity in preclinical models of AR mutation or overexpression, both common mechanisms of resistance to currently available AR-targeted therapies. Arvinas believes the differentiated pharmacology of ARV-110, including its iterative activity, has the potential to translate into improved clinical outcomes for patients.